Form 4: Ionis Pharmaceuticals Executive Receives Stock Options

Shannon L. Devers, EVP and Chief Human Resources Officer at Ionis Pharmaceuticals, was granted 22,000 stock options on January 2, 2025.

Summary

• Shannon L. Devers, an executive at Ionis Pharmaceuticals, received 22,000 non-qualified stock options on January 2, 2025.
• The options have an exercise price of $34.69 per share.
• The options vest over a period of four years, with 25% vesting on January 2, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• Following this transaction, Ms. Devers directly owns 22,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, used to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry, with vesting schedules typically ranging from three to five years.
• The vesting schedule of 25% after one year and the remainder over the next three years is a common structure.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, equity incentive plan, executive compensation, insider trading, Ionis Pharmaceuticals, vesting